CoChat

BCL-XL is crucial for progression through the adenoma-to-carcinoma sequence of colorectal cancer

Open access
Ramesh, Prashanthi, Lannagan, Tamsin R. M., Jackstadt, Rene, Atencia Taboada, Lidia, Lansu, Nico, Wirapati, Pratyaksha, van Hooff, Sander R., Dekker, Danielle, Pritchard, Jessica, Kirov, Aleksandar B., van Neerven, Sanne M., Tejpar, Sabine, Kops, Geert J. P. L., Sansom, Owen J., Medema, Jan Paul · 2021 · Cell Death & Differentiation

The DOI matches its Crossref record; 63 of the 65 references it cites were found in a registry or an index.

Abstract

Evasion of apoptosis is a hallmark of cancer, which is frequently mediated by upregulation of the antiapoptotic BCL-2 family proteins. In colorectal cancer (CRC), previous work has highlighted differential antiapoptotic protein dependencies determined by the stage of the disease. While intestinal stem cells (ISCs) require BCL-2 for adenoma outgrowth and survival during transformation, ISC-specific MCL1 deletion results in disturbed intestinal homeostasis, eventually contributing to tumorigenesis. Colon cancer stem cells (CSCs), however, no longer require BCL-2 and depend mainly on BCL-XL for their survival. We therefore hypothesized that a shift in antiapoptotic protein reliance occurs in ISCs as the disease progresses from normal to adenoma to carcinoma. By targeting antiapoptotic proteins with specific BH3 mimetics in organoid models of CRC progression, we found that BCL-2 is essential only during ISC transformation while MCL1 inhibition did not affect adenoma outgrowth. BCL-XL, on the other hand, was crucial for stem cell survival throughout the adenoma-to-carcinoma sequence. Furthermore, we identified that the limited window of BCL-2 reliance is a result of its downregulation by miR-17-5p, a microRNA that is upregulated upon APC -mutation driven transformation. Here we show that BCL-XL inhibition effectively impairs adenoma outgrowth in vivo and enhances the efficacy of chemotherapy. In line with this dependency, expression of BCL-XL , but not BCL-2 or MCL1 , directly correlated to the outcome of chemotherapy-treated CRC patients. Our results provide insights to enable the rational use of BH3 mimetics in CRC management, particularly underlining the therapeutic potential of BCL-XL targeting mimetics in both early and late-stage disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41418-021-00816-w

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 BCL-2 and BCL-XL are essential for ISC survival during transformation. a Overview of the organoid clonogenic assay. b–d Graphs depict relative outgrowth (number of organoid structures relative to the number prior to treatment and reseeding) of proximal small intestine (SIP)-derived organoid structures quantified 3 days after passaging for the indicated genotype, either without treatment or upon treatment with 1 µM b ABT-199, c A-1155463 and WEHI-539, or d AZD5991, at the time of induction. Each dot represents a replicate (minimal n = 7 per condition, n = 3 independent experiments), error bars indicate s.e.m. ***p < 0.001, ****p < 0.0001, student’s t-test. e, f Graphs depict relative outgrowth of colon-derived organoid structures quantified 3 days after passaging for the indicated genotype, upon treatment with 1 µM e ABT-199 and A-1155463 or f AZD5991, at the time of induction. Each dot represents a replicate (minimal n = 5 per condition, n = 2 independent experiments), error bars indicate s.e.m. *p < 0.05, **p < 0.01, ordinary one-way ANOVA.
Fig. 1 BCL-2 and BCL-XL are essential for ISC survival during transformation. a Overview of the organoid clonogenic assay. b–d Graphs depict relative outgrowth (number of organoid structures relative to the number prior to treatment and reseeding) of proximal small intestine (SIP)-derived organoid structures quantified 3 days after passaging for the indicated genotype, either without treatment or upon treatment with 1 µM b ABT-199, c A-1155463 and WEHI-539, or d AZD5991, at the time of induction. Each dot represents a replicate (minimal n = 7 per condition, n = 3 independent experiments), error bars indicate s.e.m. ***p < 0.001, ****p < 0.0001, student’s t-test. e, f Graphs depict relative outgrowth of colon-derived organoid structures quantified 3 days after passaging for the indicated genotype, upon treatment with 1 µM e ABT-199 and A-1155463 or f AZD5991, at the time of induction. Each dot represents a replicate (minimal n = 5 per condition, n = 2 independent experiments), error bars indicate s.e.m. *p < 0.05, **p < 0.01, ordinary one-way ANOVA.CC BY · PubMed Central
Fig. 2 BCL-2 dependence is lost immediately after transformation. a, b Graphs depict relative outgrowth of human normal colon organoids a WT1 and b WT2 quantified 3 days after passaging, upon treatment with 1 µM ABT-199 or A-1155463. Each dot represents a replicate (minimal n = 9 per condition, n = 3 independent experiments), error bars indicate s.e.m. c, d Graphs depict relative outgrowth of human APCKO organoids quantified 3 days after passaging, upon treatment with indicated doses of c ABT-199 or d A-1155463. Each dot represents a replicate (minimal n = 9 per condition, n = 3 independent experiments), error bars indicate s.e.m. ****p < 0.0001, ordinary one-way ANOVA. e Cleaved caspase-3 stained human normal (WT) and APCKO organoids after 24 h treatment with 300 nM ABT-199 or A-1155463. Scale bars, 200 µm. f Images represent the outgrowth of APCKO organoids after transduction with either control or BCL-XL targeting shRNA. g Dose-response curve of control vector (black) or BCL-XL overexpressing (red) APCKO organoids treated with a titration of A-1155463. Viability data measured by cell titer blue was blank corrected and normalized to untreated control. Data were represented as mean ± SD (n = 2 independent experiments). h Relative outgrowth of human mutant organoids of indicated genotypes quantified 3 days after passaging, upon treatment with 3 µM of ABT-199 or A-1155463 (n = 3 independent experiments). Error bars indicate s.e.m. *p < 0.05, ***p < 0.001, ****p < 0.0001, ordinary one-way ANOVA.
Fig. 2 BCL-2 dependence is lost immediately after transformation. a, b Graphs depict relative outgrowth of human normal colon organoids a WT1 and b WT2 quantified 3 days after passaging, upon treatment with 1 µM ABT-199 or A-1155463. Each dot represents a replicate (minimal n = 9 per condition, n = 3 independent experiments), error bars indicate s.e.m. c, d Graphs depict relative outgrowth of human APCKO organoids quantified 3 days after passaging, upon treatment with indicated doses of c ABT-199 or d A-1155463. Each dot represents a replicate (minimal n = 9 per condition, n = 3 independent experiments), error bars indicate s.e.m. ****p < 0.0001, ordinary one-way ANOVA. e Cleaved caspase-3 stained human normal (WT) and APCKO organoids after 24 h treatment with 300 nM ABT-199 or A-1155463. Scale bars, 200 µm. f Images represent the outgrowth of APCKO organoids after transduction with either control or BCL-XL targeting shRNA. g Dose-response curve of control vector (black) or BCL-XL overexpressing (red) APCKO organoids treated with a titration of A-1155463. Viability data measured by cell titer blue was blank corrected and normalized to untreated control. Data were represented as mean ± SD (n = 2 independent experiments). h Relative outgrowth of human mutant organoids of indicated genotypes quantified 3 days after passaging, upon treatment with 3 µM of ABT-199 or A-1155463 (n = 3 independent experiments). Error bars indicate s.e.m. *p < 0.05, ***p < 0.001, ****p < 0.0001, ordinary one-way ANOVA.CC BY · PubMed Central
Fig. 3 BCL-XL is crucial for stem cell survival in patient-derived adenoma and tumor organoids. a, b Graphs depict relative outgrowth of human tubular adenomas TA1 and TA5 quantified 3 days after passaging, upon treatment with indicated doses of a ABT-199 or b A-1155463. Each dot represents a replicate (minimal n = 6 per condition, n = 3 independent experiments), error bars indicate s.e.m. *p < 0.05, **p < 0.01, ****p < 0.0001, ordinary one-way ANOVA. c Cleaved caspase-3 stained human TAs after 24 h treatment with 300 nM ABT-199 or A-1155463. Scale bars, 250 µm. d Graphs depict relative outgrowth of human tubular adenomas TA1 and TA5 quantified 3 days after passaging, upon treatment with indicated doses of AZD5991. Each dot represents a replicate (minimal n = 6 per condition, n = 3 independent experiments), error bars indicate s.e.m. e Relative viability of patient-derived CRC organoids upon treatment with a titration of ABT-199 (orange), A-1155463 (green), or AZD5991 (blue) (n = 3 independent experiments). Error bars indicate s.e.m.
Fig. 3 BCL-XL is crucial for stem cell survival in patient-derived adenoma and tumor organoids. a, b Graphs depict relative outgrowth of human tubular adenomas TA1 and TA5 quantified 3 days after passaging, upon treatment with indicated doses of a ABT-199 or b A-1155463. Each dot represents a replicate (minimal n = 6 per condition, n = 3 independent experiments), error bars indicate s.e.m. *p < 0.05, **p < 0.01, ****p < 0.0001, ordinary one-way ANOVA. c Cleaved caspase-3 stained human TAs after 24 h treatment with 300 nM ABT-199 or A-1155463. Scale bars, 250 µm. d Graphs depict relative outgrowth of human tubular adenomas TA1 and TA5 quantified 3 days after passaging, upon treatment with indicated doses of AZD5991. Each dot represents a replicate (minimal n = 6 per condition, n = 3 independent experiments), error bars indicate s.e.m. e Relative viability of patient-derived CRC organoids upon treatment with a titration of ABT-199 (orange), A-1155463 (green), or AZD5991 (blue) (n = 3 independent experiments). Error bars indicate s.e.m.CC BY · PubMed Central
Fig. 4 BCL-XL inhibition impairs adenoma outgrowth in vivo. a Representative images from a colonoscopy of VillinCreERApcfl/fl mice, three weeks after being induced with a single injection of 4-hydroxytamoxifen into the colonic submucosa. ABT-199 and A-1155463 treated mice received 100 mg/kg of drug for 2 days prior to induction followed by treatment every other day until day 28. Red arrows indicate tumors. b Quantification of colonic tumor size (normalized to the size of the lumen) of mice described in (a), n = 6 for vehicle, n = 4 for ABT-199, and n = 5 for A-1155463, one-way Mann–Whitney U-test, p = 0.47 (vehicle vs ABT-199) and P = 0.02 (vehicle vs A-1155463). Data represents mean ± SD.
Fig. 4 BCL-XL inhibition impairs adenoma outgrowth in vivo. a Representative images from a colonoscopy of VillinCreERApcfl/fl mice, three weeks after being induced with a single injection of 4-hydroxytamoxifen into the colonic submucosa. ABT-199 and A-1155463 treated mice received 100 mg/kg of drug for 2 days prior to induction followed by treatment every other day until day 28. Red arrows indicate tumors. b Quantification of colonic tumor size (normalized to the size of the lumen) of mice described in (a), n = 6 for vehicle, n = 4 for ABT-199, and n = 5 for A-1155463, one-way Mann–Whitney U-test, p = 0.47 (vehicle vs ABT-199) and P = 0.02 (vehicle vs A-1155463). Data represents mean ± SD.CC BY · PubMed Central
Fig. 5 BCL-2 expression is decreased upon transformation. a, b mRNA expression of a BCL-2 and b BCL-XL in a compiled dataset of colon normal, adenoma and tumor samples. c, d Immunohistochemical analysis of c BCL-2 and d BCL-XL expression in normal and adjacent tumor tissue. Scale bars, 200 µm. e, f Gene expression (raw mean counts) of e BCL-2 and f BCL-XL in a single cell RNA-Seq dataset of normal and tumor samples, separated by cell type. Data were represented as mean ± SE and node size indicates the number of cells per sample. Samples in different cell types are shown in the same order. p < 0.005 for the fold change in BCL-2 and BCL-XL expression in normal vs tumor epithelial cells. g, h Intracellular FACs staining of g BCL-2 and h BCL-XL in the PTK7 high stem cell fraction of normal and APCKO human organoids. (n = 3 independent experiments). Error bars indicate s.e.m. **p < 0.01, student’s t-test.
Fig. 5 BCL-2 expression is decreased upon transformation. a, b mRNA expression of a BCL-2 and b BCL-XL in a compiled dataset of colon normal, adenoma and tumor samples. c, d Immunohistochemical analysis of c BCL-2 and d BCL-XL expression in normal and adjacent tumor tissue. Scale bars, 200 µm. e, f Gene expression (raw mean counts) of e BCL-2 and f BCL-XL in a single cell RNA-Seq dataset of normal and tumor samples, separated by cell type. Data were represented as mean ± SE and node size indicates the number of cells per sample. Samples in different cell types are shown in the same order. p < 0.005 for the fold change in BCL-2 and BCL-XL expression in normal vs tumor epithelial cells. g, h Intracellular FACs staining of g BCL-2 and h BCL-XL in the PTK7 high stem cell fraction of normal and APCKO human organoids. (n = 3 independent experiments). Error bars indicate s.e.m. **p < 0.01, student’s t-test.CC BY · PubMed Central
Fig. 6 MiR-17-5p regulates BCL-2 expression in APC-mutant organoids. a BCL-2 mutation and methylation status in CRC tumors of the TCGA COAD dataset, analyzed on cBioPortal. b mRNA expression of BCL-2 in decitabine treated APCKO organoids (n = 2 independent experiments). Error bars indicate s.e.m. c Single cell karyotype-seq showing the ploidy in individual cells of TA1 and TA5. Graphs show individual cells (horizontal lines) and colors indicate copy number state for a given chromosome (columns). d, e qRT-PCR analysis of d miR-17-5p and e miR-18a-3p expression in human normal, APCKO and TA cultures, normalized to U6 snRNA expression. Data represent mean ± s.e.m. f, g Correlation of f miR-17-5p and g mir-18a-3p expression data from (d) and (e), respectively to BCL-2 protein levels measured by intracellular FACS. P values are determined by two-tailed Pearson’s correlation. h Intracellular FACS staining of BCL-2 protein levels in human APCKO organoids transduced with control, miR-17-5p, or miR-18a-3p anti-sense(AS) microRNA inhibitors (n = 3 independent experiments). Error bars indicate s.e.m. **p < 0.01, student’s t-test. i Correlation of miR-17 and BCL-2 expression in the TCGA COAD dataset.
Fig. 6 MiR-17-5p regulates BCL-2 expression in APC-mutant organoids. a BCL-2 mutation and methylation status in CRC tumors of the TCGA COAD dataset, analyzed on cBioPortal. b mRNA expression of BCL-2 in decitabine treated APCKO organoids (n = 2 independent experiments). Error bars indicate s.e.m. c Single cell karyotype-seq showing the ploidy in individual cells of TA1 and TA5. Graphs show individual cells (horizontal lines) and colors indicate copy number state for a given chromosome (columns). d, e qRT-PCR analysis of d miR-17-5p and e miR-18a-3p expression in human normal, APCKO and TA cultures, normalized to U6 snRNA expression. Data represent mean ± s.e.m. f, g Correlation of f miR-17-5p and g mir-18a-3p expression data from (d) and (e), respectively to BCL-2 protein levels measured by intracellular FACS. P values are determined by two-tailed Pearson’s correlation. h Intracellular FACS staining of BCL-2 protein levels in human APCKO organoids transduced with control, miR-17-5p, or miR-18a-3p anti-sense(AS) microRNA inhibitors (n = 3 independent experiments). Error bars indicate s.e.m. **p < 0.01, student’s t-test. i Correlation of miR-17 and BCL-2 expression in the TCGA COAD dataset.CC BY · PubMed Central
Fig. 7 BCL-XL expression is predictive for chemotherapy response. a Phase-contrast images of p16T and p24aT human CRC organoids treated for 72 h with 10 µM oxaliplatin alone and in combination with 30 nM A-1155463. Scale bars, 250 µm. b, c 6 × 7 dose matrices of b p16T and c p24aT human CRC organoids treated with oxaliplatin in combination with A-1155463 for 5 days. Percentage inhibition was calculated from viability data measured by cell titer blue, after normalizing to control. Data were the average of two independent experiments. Bliss synergy scores were calculated for each dose combination and positive scores indicate synergistic effects. d–f Kaplan–Meier analysis of the relapse free survival probability of micro-satellite stable CM2 and CM3 patients in the Marisa dataset who received adjuvant chemotherapy (n = 119), based on a cut-off of median expression of d BCL-2, e MCL-1, or f BCL-XL. P values are based on the log-rank test. Adj Chemo patients who received adjuvant chemotherapy, MSS microsatellite stable, CMS2/3 consensus molecular subtype 2/3.
Fig. 7 BCL-XL expression is predictive for chemotherapy response. a Phase-contrast images of p16T and p24aT human CRC organoids treated for 72 h with 10 µM oxaliplatin alone and in combination with 30 nM A-1155463. Scale bars, 250 µm. b, c 6 × 7 dose matrices of b p16T and c p24aT human CRC organoids treated with oxaliplatin in combination with A-1155463 for 5 days. Percentage inhibition was calculated from viability data measured by cell titer blue, after normalizing to control. Data were the average of two independent experiments. Bliss synergy scores were calculated for each dose combination and positive scores indicate synergistic effects. d–f Kaplan–Meier analysis of the relapse free survival probability of micro-satellite stable CM2 and CM3 patients in the Marisa dataset who received adjuvant chemotherapy (n = 119), based on a cut-off of median expression of d BCL-2, e MCL-1, or f BCL-XL. P values are based on the log-rank test. Adj Chemo patients who received adjuvant chemotherapy, MSS microsatellite stable, CMS2/3 consensus molecular subtype 2/3.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 63 references

Cited by

See all 52

Metadata

Authors
Ramesh, P., Lannagan, T. R. M., Jackstadt, R., Atencia Taboada, L., Lansu, N., Wirapati, P., van Hooff, S. R., Dekker, D., Pritchard, J., Kirov, A. B., van Neerven, S. M., Tejpar, S., Kops, G. J. P. L., Sansom, O. J., & Medema, J. P.
Affiliations
  • Oncode Institute (NL)
  • Cancer Research UK Scotland Institute (GB)
  • University Medical Center Utrecht (NL)
  • SIB Swiss Institute of Bioinformatics (CH)
  • KU Leuven (BE)
Corresponding author
Medema, Jan Paul
Venue
Cell Death & Differentiation
Published
2021-06-11
Volume
28
Issue
12
Pages
3282-3296
ISSN
  • 1350-9047 (ISSN-L)
  • 1476-5403
OpenAlex
W3166580483
Cited by
52
References
65
Citations by year
2026: 4 · 2025: 13 · 2024: 8 · 2023: 15 · 2022: 11 · 2021: 1
FWCI
2.75
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Death and Differentiation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • KNAW Research Portal (The Royal Netherlands Academy of Arts and Sciences) (publishedVersion, other-oa)
  • SERVAL (Université de Lausanne) (publishedVersion, cc-by)
  • Pure Amsterdam UMC (acceptedVersion, cc-by)
  • IRIS (submittedVersion, cc-by)
  • Lirias (submittedVersion, cc-by)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
Funders
Cancer Research UK (A21139/, A17196/, 21139)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
Keywords
Bcl-xL, colorectal cancer, adenoma-carcinoma sequence, intestinal stem cells, cancer stem cells, apoptosis evasion, Bcl-2, Mcl-1, BH3 mimetics, miR-17-5p, APC mutation, colorectal organoids, chemotherapy response
MeSH terms
Adenoma, Animals, Female, Humans, Male, Colorectal Neoplasms, Survival Analysis, Apoptosis, Disease Progression, bcl-X Protein, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BCL-XL is crucial for progression through the adenoma-to-carcinoma sequence of colorectal cancer. https://app.cochat.ai/papers/10.1038/s41418-021-00816-w
The paper
Ramesh, P., Lannagan, T. R. M., Jackstadt, R., Atencia Taboada, L., Lansu, N., Wirapati, P., van Hooff, S. R., Dekker, D., Pritchard, J., Kirov, A. B., van Neerven, S. M., Tejpar, S., Kops, G. J. P. L., Sansom, O. J., & Medema, J. P. (2021). BCL-XL is crucial for progression through the adenoma-to-carcinoma sequence of colorectal cancer. Cell Death & Differentiation. https://doi.org/10.1038/s41418-021-00816-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.